{"schema_version":"secwatch.filing_event.v1","accession":"0001792044-26-000037","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2026-08-06T11:56:03+00:00","discovered_at":"2026-08-06T12:00:03.469558+00:00","generated_at":"2026-08-06T12:00:15.470223+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viatris Q2 2026: Revenue $3.8B (+5%), GAAP net loss $119M, raises full-year guidance","bullets":["Total revenues $3.8B, up 5% reported and 3.5% operationally vs Q2 2025; GAAP net loss $119M.","Adjusted EBITDA $1.2B, up 8% operationally; gross leverage ratio reduced to 2.9x.","Raised 2026 financial guidance midpoints for all metrics; expects balanced H2.","Returned ~$550M to shareholders including ~$270M share repurchases through early August.","Pipeline milestones: U.S. FDA approval of Gwyn Lo; sale of global rights to Tyrvaya."],"urls":{"canonical":"https://secwatch.observer/filing/0001792044-26-000037","json":"https://secwatch.observer/filing/0001792044-26-000037.json","markdown":"https://secwatch.observer/filing/0001792044-26-000037.md","text":"https://secwatch.observer/filing/0001792044-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/0001792044-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/vtrs-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:00:15.470223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}